| Date | Form | Description | Docs | XBRL | Pages |
| 06/10/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
19 |
| 03/11/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
19 |
| 09/01/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
20 |
| 06/10/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
23 |
| 03/11/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
30 |
| 09/08/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
37 |
| 06/09/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
60 |
| 03/09/20 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
35 |
| 09/06/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
84 |
| 06/12/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
39 |
Latest News & Events
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
Read More...Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Read More...Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Read More...